Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. | ...

Aurobindo Pharma has received final USFDA approval to launch generic Rivaroxaban 2.5mg tablets in the US, targeting a $447 ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

Empower will be occupying 170,000 square feet of the existing Aurobindo Pharma building at the ... The article Empower Pharmacy To Open New Manufacturing Site In East Windsor appeared first ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

Nomura believes that pharma tariffs may not be imposed today, but postponed to a later date. It said the US may reiterate its stance on tariffs for drugs manufactured outside the US in due course.

Gland Pharma surged 7.33 per cent to Rs 1,647.65. Aurobindo Pharma, the largest Indian generic company with US sales, soared ...

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, reports successful trial results for BP16, a new drug showing promise ...

February 6, 2025 India's Aurobindo Pharma posts third-quarter profit drop ... demand amid signals the rally will sustain. Reuters, the news and media division of Thomson Reuters, is the world ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received successful trial results for its new bone treatment medicine. The drug, called BP16, is a biosimilar of an existing ...